Oryzon Genomics News Today

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th...

Funding provided by Nice & Green SA, a Swiss private investor This CB Program supersedes the previous oneTo extend its cash runway and continue the...

Oryzon’s CEO, Dr. Carlos Buesa, will attend the LSX Investival Showcase, to be held on November 13 at at Old Billingsgate in London (UK). Click on link for more info about the LSX Investival Showcase 2023

QEV Technologies and SPEAR Investments confirm expected business combination and listing on Euronext Amsterdam QEV Technologies is a fast-growing...

Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial

Oryzon Genomics has nominated a new central nervous system (CNS) clinical development candidate, ORY-4001, for the treatment of rare CNS disorders including Charcot-Marie-Tooth (CMT) disease and amyotrophic

Collaborative study with Fox Chase Cancer Center Trial will assess the safety and efficacy of iadademstat in pulmonary and extrapulmonary NECsPart of a...

ORYZON announces First Patient In in NET, a collaborative Phase II basket study with iadademstat in R/R patients with neuroendocrine carcinomas

MADRID (Reuters) - Shares of Spanish biopharma company Oryzon Genomics soared on Tuesday after the U.S. National Cancer Institute agreed to test a new...

Oryzon invests $4.2 million in R&D in the first quarter 2022...